A PHASE I TRIAL OF TARGETED IMMUNOTHERAPY WITH DARATUMUMAB FOLLOWING MYELOABLATIVE TOTAL BODY IRRADIATION (TBI)-BASED CONDITIONING AND ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATON IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS WITH HIGH-RISK T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND LYMPHOMA (T- ALL/T-LLy) (ALLO-T-DART) (IND 159396): A PTCTC FACILITATED STUDY
Titel:
A PHASE I TRIAL OF TARGETED IMMUNOTHERAPY WITH DARATUMUMAB FOLLOWING MYELOABLATIVE TOTAL BODY IRRADIATION (TBI)-BASED CONDITIONING AND ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATON IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS WITH HIGH-RISK T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND LYMPHOMA (T- ALL/T-LLy) (ALLO-T-DART) (IND 159396): A PTCTC FACILITATED STUDY
Auteur:
Quigg, T. Flower, A. Teachey, D. Lim, M. Chu, Y. Harrison, L. Morris, E. Gardenswartz, A. Hochberg, J. Ozkaynak, M. Rosenblum, J. Milner, J. Pehlivan, K. Levendoglu-Tugal, O. Fabricatore, S. Wolownik, K. Ayello, J. Rigot, O. Klejmont, L. Campbell, M. Gonzalez, I. Otero, N. Budhram, A. Mintzer, E. Mahanti, H. Dufresne, J. Liu, D. Ahmed, T. Steinberg, A. Sweeney, R. McHale, P. Islam, H. Gerard, P. Moorthy, C. Voss, S. Miles, R. Audino, A. Mo, X. Stanek, J. Olshen, A. Hermiston, M. Seif, A. Cairo, M.